Detalles de la búsqueda
1.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lancet
; 402(10400): 451-463, 2023 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37423228
2.
A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy.
J Oncol Pharm Pract
; : 10781552241242096, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38533561
3.
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Oncologist
; 28(4): e205-e211, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905578
4.
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
J Transl Med
; 21(1): 725, 2023 10 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37845764
5.
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
Future Oncol
; 19(21): 1461-1472, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37249038
6.
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.
Future Oncol
; 18(40): 4457-4464, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36946237
7.
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.
Int J Mol Sci
; 23(16)2022 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36012655
8.
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
Int J Mol Sci
; 23(23)2022 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36498861
9.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 22(10): 1438-1447, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34499874
10.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
; 378(24): 2288-2301, 2018 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863955
11.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Breast J
; 27(4): 359-362, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677841
12.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
13.
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy.
Future Oncol
; 16(20): 1433-1439, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32437242
14.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31122901
15.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Br J Cancer
; 120(1): 57-62, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377342
16.
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Oncologist
; 24(11): e1165-e1171, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30996007
17.
Could the molecular profile aid in predicting occult nodal metastasis in early-stage lung adenocarcinoma?
Surg Today
; 54(3): 288-289, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733185
18.
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Tumour Biol
; 40(11): 1010428318815047, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30486741
19.
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Future Oncol
; 14(15): 1477-1486, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29376400
20.
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Proc Natl Acad Sci U S A
; 112(48): 14924-9, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26627242